On June 2, 2022 Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported that Thomas Butler, Chief Executive Officer and Chairman of the Board, will participate in a fireside chat and meet with investors at the in-person Jefferies Healthcare Conference (Press release, Biomea Fusion, JUN 2, 2022, View Sourcenews-releases/news-release-details/biomea-fusion-participate-jefferies-healthcare-conference" target="_blank" title="View Sourcenews-releases/news-release-details/biomea-fusion-participate-jefferies-healthcare-conference" rel="nofollow">View Source [SID1234615485]). The fireside chat will take place on Wednesday, June 8th at 2:30pm Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed at View Source and will be available for 90 days following the presentation.

On June 2, 2022 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported results of a post-hoc study analysis showing that ES-SCLC patients who received trilaciclib prior to chemotherapy had a lower incidence of single- and multilineage myelosuppressive events—fewer cases of severe neutropenia, severe anemia, and severe thrombocytopenia—compared to patients receiving placebo (Press release, G1 Therapeutics, JUN 2, 2022, View Source [SID1234615418]). Moreover, the proportion of patients who experienced at least one multilineage myelosuppressive event was lower in the trilaciclib arm compared to the placebo arm . The data, derived from a post-hoc analysis of Phase 2 trials, were presented in a poster at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Myelosuppression is a major toxicity of chemotherapy treatment for patients with extensive-stage small cell lung cancer that often results in chemotherapy dose delays and dose reductions, both of which can compromise clinical outcomes," said Jerome Goldschmidt, M.D., medical oncologist with Blue Ridge Cancer Care in Blacksburg, VA, and lead author of the poster. "Both the patients and the healthcare system at large bear the complications of myelosuppressive events such as neutropenia, anemia, and thrombocytopenia, so it is imperative that we achieve clinically meaningful reductions in myelosuppression in multiple cell lineages and its consequences utilizing novel therapies such as trilaciclib."

In the analysis, the researchers calculated the number of patients who experienced single lineage and multilineage myelosuppressive events as well as the total number of events each person experienced in both first-line and second/third-line chemotherapy settings. Only severe grade events (grade ≥ 3 per the National Cancer Institute) were included in the analysis, and 75 percent of patients were in the first-line setting.

Results of the analysis showed that throughout cycles one through four of first-line therapy, fewer patients treated with trilaciclib experienced single-lineage (neutrophil, red blood cell or platelet lineages) and multilineage myelosuppressive events—and fewer events occurred per person—than patients who received placebo.

Specifically, analyses of the pooled data showed that patients receiving trilaciclib in the first-line setting experienced fewer single-lineage myelosuppressive events, including:

a 75% reduction (56.7% to 14.4%) in severe neutropenia compared to patients receiving placebo
a 50% reduction (17.8% to 8.9%) in severe anemia compared to patients receiving placebo
a 100% reduction (12.2% to 0.0%) in severe thrombocytopenia compared to patients receiving placebo
Additionally, analyses of the pooled data showed that patients receiving trilaciclib in the first-line setting experienced fewer concurrent, multilineage myelosuppressive events, including:

a 100% reduction (2.2% to 0.0%) in concurrent severe anemia, severe neutropenia, severe thrombocytopenia compared to patients receiving placebo.
a 100% reduction (13.3% to 0.0%) in concurrent severe neutropenia and severe thrombocytopenia compared to patients receiving placebo
a 50% reduction (4.4% to 2.2%) in concurrent severe neutropenia and severe anemia compared to patients receiving placebo
a 33% reduction (3.3% to 2.2%) in concurrent severe anemia and severe thrombocytopenia compared to patients receiving placebo
Concurrent events were defined as having two or three lineage-specific myelosuppressive events overlap for at least one day.

The ASCO (Free ASCO Whitepaper) poster, titled, "Impact of Trilaciclib on Multilineage Chemotherapy-Induced Myelosuppression Events in Patients with Extensive-Stage Small-Cell Lung Cancer: Post-Hoc Analyses of Data from Randomized Clinical Trials," can be found here.

About Small Cell Lung Cancer

In the United States, approximately 30,000 small cell lung cancer patients are treated annually. SCLC, one of the two main types of lung cancer, accounts for about 10% to 15% of all lung cancers. SCLC is an aggressive disease and tends to grow and spread faster than NSCLC. It is usually asymptomatic; once symptoms do appear, it often indicates that the cancer has spread to other parts of the body. About 70% of people with SCLC will have cancer that has metastasized at the time they are diagnosed. The severity of symptoms usually increases with increased cancer growth and spread. From the time of diagnosis, the general 5-year survival rate for people with SCLC is 6%. The five-year survival rates for limited-stage (the cancer is confined to one side of the chest) SCLC is 12% to 15%, and for extensive stage (cancer has spread to the other lung and beyond), survival rates are less than 2%. Chemotherapy is the most common treatment for ES-SCLC. A majority (>90%) of ES-SCLC patients receive first-line chemotherapy at the time of treatment initiation.

On June 2, 2022 Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, reported that Chief Executive Officer, Bill Newell, will participate in two upcoming investor conferences (Press release, Sutro Biopharma, JUN 2, 2022, View Source [SID1234615436]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Jefferies Healthcare Conference
Format: Presentation
Date: Thursday, June 9, 2022
Time: 8:00 a.m. ET / 5:00 a.m. PT
Location: New York City

The JMP Securities Life Sciences Conference
Format: Fireside Chat
Date: Thursday, June 16, 2022
Time: 9:30 a.m. ET / 6:30 a.m. PT
Location: New York City

Live webcasts of each presentation can be accessed through the Events and Presentations page of the Investor Relations section on the company’s website at www.sutrobio.com. Archived replays of the webcasts will be available on the company’s website for approximately 30 days following each live presentation.

On June 2, 2022 NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, reported plans to commercially unveil the CosMx Spatial Molecular Imager (SMI) and its new spatial informatics portal during a Spatial Multiomic Symposium, which will be held on Monday, June 6 from noon to 4:00 pm EDT (Press release, NanoString Technologies, JUN 2, 2022, View Source [SID1234615452]). The event will be live-streamed and held in person, and details can be found here: Spatial Multiomics Symposium – NanoString. In addition, scientists will present 20 studies demonstrating the power of NanoString spatial biology platforms during the scientific portion of the AGBT General Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CosMx SMI enables high-resolution imaging of more than 1,000 RNA and over 100 protein analytes within morphologically intact whole tissue sections. The technology combines the power of high-plex profiling with high-resolution imaging, allowing researchers to visualize and quantify gene and protein expression at single cell and subcellular resolutions within both fresh frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples. CosMx SMI serves scientists across the continuum of research using a tunable workflow that can prioritize either unbiased whole-slide imaging at high-plex for discovery or high-throughput biology-driven analysis for translation.

NanoString is dedicated to developing spatial biology solutions for any scale of research. The GeoMx DSP is the leading platform for measuring whole transcriptome at high-throughput in multi-cellular functional regions and the CosMx SMI extends capability to single cell and subcellular resolution across the entire tissue section. Together, GeoMx DSP and CosMx SMI technologies provide unprecedented scientific power for novel spatial discoveries.

Spatial biology experiments are data-intensive, creating up to 1 terabyte of data per sample. NanoString is developing a new cloud-based spatial informatics portal that will provide researchers with a scalable solution to store large GeoMx and CosMx datasets, reduce compute times, and enable secure data sharing and collaboration across institutes.

The Spatial Multiomic Symposium will showcase the application of these powerful tools to resolve biological heterogeneity. Attendees will learn about the latest innovations and will have the opportunity to hear how leading experts are applying these technologies to make novel discoveries in immunology, infectious diseases, oncology and neuroscience.

"We believe spatial biology is the next revolution in life sciences, and we’re honored to bring together experts to showcase cutting-edge spatial technologies and techniques," said Brad Gray, president and CEO, NanoString Technologies. "The volume and quality of NanoString-driven science being presented at AGBT 2022 is a testament to the power of our spatial biology ecosystem."

The Spatial Multiomic Summit Agenda: Speakers and Scientific Presentations

Keynote: Spatial gene expression changes in human skin biology induced from spaceflight: Christopher Mason, Ph.D., Professor; Director, WorldQuant Initiative for Quantitative Prediction; Physiology and Biophysics, Weill Cornell Medicine
Spatially resolved, single cell atlas of human pancreatic islets of Langerhans in type 2 diabetic and healthy controls: Grant Kolar, M.D., Ph.D., Assistant Research Professor Director, Research Microscopy and Histology Core, St. Louis University
Deep spatiotemporal insights into COVID-19: a multi-organ study: Arutha Kulasinghe, Ph.D., National Health and Medical Research Council Research Fellow, The University of Queensland
Spatial reconstruction of joint inflammation in rheumatoid arthritis: Kevin Wei, M.D., Ph.D., Assistant Professor of Medicine, Brigham and Women’s Hospital
Spatially resolved Alzheimer’s disease in mouse model: Miranda Orr, Ph.D., Assistant Professor, Gerontology and Geriatric Medicine, Wake Forest University School of Medicine
To learn more and register for the event, please visit: Spatial Multiomics Symposium – NanoString

At AGBT 2022, 20 posters and oral presentations will showcase unique biological insights generated using NanoString’s spatial platforms. These abstracts include studies exploring spatial biology using the GeoMx DSP and the CosMx SMI platforms.

"As single-cell resolution spatial transcriptomics and proteomics pioneer the next frontier in spatial biology, our understanding of fundamental processes in biology will deepen and perhaps pave the way for next-generation diagnostic and pathology tools," said Joe Beechem, chief scientific officer, NanoString Technologies. "The CosMx SMI system is ideal for deeper single-cell exploration downstream of whole transcriptome analysis carried out on GeoMx DSP and the two systems can essentially be used for complementary experiments on a set of samples."

Several studies and presentations that feature NanoString’s spatial biology platforms are highlighted below.

Oral Presentations

Multicellular spatial neighborhoods in pancreatic cancer remodeled by neoadjuvant treatment will be presented by Will Hwang, M.D., Ph.D., radiation oncologist and research fellow, Massachusetts General Hospital Cancer Center/Harvard Medical School, on June 6 from 6:05-6:25 pm. Discover the unique interaction between malignant cells and nerves/microenvironment during the response to treatment for PDAC, using GeoMx DSP and CosMx SMI platforms.

Building a spatial single-cell multi-omics atlas and cellular interactome for skin cancer will be presented by Quan Nguyen, Ph.D., the University of Queensland on June 7 from 7:50-8:10 pm. Learn how CosMx profiling enables spatial interactome analysis that provides new insights in the development of skin cancer. This will be a comparison of six spatial platforms.

High-plex (> 1000), multi-omic (RNA plus protein), spatial molecular imaging with sub-cellular resolution in FFPE tissue, will be presented by Joe Beechem, Ph.D., chief scientific officer, NanoString Technologies. Concurrent sessions will run from 8:50-9:10 pm on June 8. Learn how high-plex multi-omic (RNA and protein) targets detected in FFPE samples using CosMx SMI, at subcellular and single-cell resolution in >1 million cells from a single slide uncovers novel biological insights that were previously lost in space.

Scientific Posters

Poster: Spatial characterization of the tumor microenvironment in pancreatic cancer with whole transcriptome profiling and high plex single-cell imaging.
David Ting, M.D., Chief Medical Information Officer, Mass General Physicians Organization, Co-Director, MGH Center for Innovation in Digital HealthCare, Assistant Professor, Harvard Medical School
See the origin of exosomes in tumor microenvironments and the effect of their migrations in pancreatic cancer tissues using the CosMx SMI platform.

Poster: Characterization of human brain organoids with single-cell resolution and molecular specificity
Florent Ginhoux, Ph.D., Senior Principal Investigator · Singapore Immunology Network, Agency for Science, Technology and Research
Learn how CosMx single-cell imager enables unique analyses and understanding of human brain organoid cells in space.

Poster: Spatially-mapped quantitative single-cell characterization of PD-L1-related RNA microenvironments in triple-negative breast cancer
Aubrey Thompson, Ph.D., Co-director of the Mayo Clinic Breast Cancer Translational Genomics Program
Learn how CosMx and GeoMx spatial platforms generate consistent data for clinical biomarkers of response to IO therapy.

Poster: Spatial Single Cell characterization of SIV reservoirs in lymphoid tissues and B cell follicles in rhesus macaques
Jake Estes, Ph.D., Professor, VGTI-Vaccine and Gene Therapy Institute; Chief, Division of Pathobiology & Immunology, Oregon National Primate Research Center
Uncover how subcellular localization of SIV RNAs in NHP revealed by CosMx and response to drug targets in infected-cell microenvironments studied using GeoMx DSP provides novel analysis tools for vaccine development.

Poster: High-plex spatial single cell in situ analysis of lung SARS-CoV-2
Arutha Kulasinghe, Ph.D., NHMRC Research Fellow, Queensland University of Technology
Discover the consistent insights in COVID biology and biomarkers uncovered by the CosMx SMI and GeoMx DSP platforms at different scales.

To see the complete list of 2022 AGBT posters and learn more about the data presented on the GeoMx DSP and CosMx SMI platforms, visit NanoString’s AGBT event page.

On June 2, 2022 Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, reported that the clinical strategy for enhancing the efficacy of its Merkel cell polyomavirus (MCPyV)-specific T cell receptor (TCR) program for the treatment of PD-1 refractory Merkel cell carcinoma (MCC), from its strategic collaboration with Fred Hutchinson Cancer Center, will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2022 (Press release, Affini-T Therapeutics, JUN 2, 2022, View Source [SID1234615468]). The poster presentation will be delivered by Joshua Veatch, M.D., Ph.D., from Fred Hutch.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We recognize that MCC patients are in desperate need of new treatments, in particular due to having no curative therapeutic options and a five-year survival rate of less than ten percent in those who have developed widespread disease," said Loïc Vincent, Ph.D., Chief Scientific Officer of Affini-T. "The clinical strategy to be presented at ASCO (Free ASCO Whitepaper) is the result of tumor biopsy analyses generated from treating MCC patients and reflects the recent addition of an MHC-I boosting molecule to the MCPyV-specific T cell Phase I/II study protocol. By enhancing MHC-I expression on MCC tumors, we hope to minimize immune system evasion and maximize the clinical efficacy of MCPyV-specific T cells to treat MCC patients."

Poster presentation details are as follows:

Title: ATTAC-MCC: Phase I/II study of Autologous CD8+ and CD4+ Transgenic T cells expressing a high-affinity MCPyV-specific TCR combined with checkpoint inhibitors and Class I MHC-upregulation in patients with metastatic MCC refractory to PD-1 axis blockade
Presenting Author: Joshua Veatch, M.D., Ph.D., Fred Hutchinson Cancer Center
Abstract Number: TPS9596
Poster Number: 186b
Poster Session Title: Melanoma/Skin Cancers
Date & Time: June 6, 2022, 2:15 PM EDT

About Merkel Cell Carcinoma and Merkel Cell Polyomavirus
Merkel cell carcinoma (MCC) is a highly aggressive skin cancer, with an incidence that has doubled in the last 20 years to approximately 3,000 cases per year in the U.S. Over one-third of patients will develop widespread disease and outcomes for these patients have been historically poor with a five-year survival rate of less than ten percent. Cancer-causing Merkel cell polyomavirus (MCPyV) is expressed in most MCC tumors and can be leveraged to target these tumors. Although immune checkpoint inhibitors (ICIs) targeting relevant biochemical pathways show promise, most MCC patients will eventually relapse. There is no standard of care for patients whose cancer has become resistant to ICIs. We believe that cellular immune therapies targeting MCPyV may provide additional clinical benefit to these patients.